Liminatus Pharma, Inc. Class A Common Stock (LIMN) 10-Year Financial Performance & Capital Metrics

LIMN • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

AboutLiminatus Pharma, Inc. operates as a clinical-stage immuno-oncology company that develops novel cancer therapies. The company is based in LA Palma, California.Show more

Revenue $0
EBITDA -$3M -152.2%
Net Income -$3M -136.9%
EPS (Diluted) -0.40 -166.7%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -
ROIC -
Debt/Equity -
Interest Coverage -21.04 -42.4%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Share count reduced 10.2% through buybacks

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Weak momentum: RS Rating 3 (bottom 3%)
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM24.57%

EPS CAGR

10Y-

5Y-

3Y-

TTM-493.27%

ROCE

10Y Avg-16.28%

5Y Avg-16.28%

3Y Avg-23.95%

Latest-

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.33B	9.92	70.86	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	720.1M	4.25	11.18	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	881.27M	2.22	-1.73	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	572.64M	7.30	-2.38			-117.82%	0.18
NKTRNektar Therapeutics	719.28M	35.36	-4.07	9.22%	-192.87%	-141.9%	1.69
IMNMImmunome, Inc.	2.52B	22.85	-4.57	-35.5%	-23.01%	-84.4%	0.03
IBRXImmunityBio, Inc.	3.89B	3.95	-6.37	22.71%	-422.28%
NRIXNurix Therapeutics, Inc.	1.91B	18.86	-6.55	-29.15%	-292.5%	-65.76%	0.05

Profit & Loss

	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0
Revenue Growth %	-	-	-	-
Cost of Goods Sold+	0	0	0	0
COGS % of Revenue	-	-	-	-
Gross Profit+	0	0	0	0
Gross Margin %	-	-	-	-
Gross Profit Growth %	-	-	-	-
Operating Expenses+	2.53M	2.71M	2.59M	2.91M
OpEx % of Revenue	-	-	-	-
Selling, General & Admin	2.53M	856K	2.59M	2.91M
SG&A % of Revenue	-	-	-	-
Research & Development	0	1.85M	0	0
R&D % of Revenue	-	-	-	-
Other Operating Expenses	0	0	0	0
Operating Income+	-2.53M	-2.71M	-2.59M	-2.91M
Operating Margin %	-	-	-	-
Operating Income Growth %	-	-0.07%	0.05%	-0.12%
EBITDA+	4.37M	-2.71M	-1.09M	-2.75M
EBITDA Margin %	-	-	-	-
EBITDA Growth %	-	-1.62%	0.6%	-1.52%
D&A (Non-Cash Add-back)	0	0	0	0
EBIT	4.37M	-2.71M	-1.09M	-2.75M
Net Interest Income+	16.84K	-219K	-165K	-385
Interest Income	16.84K	0	10K	137.72K
Interest Expense	0	219K	175K	138.1K
Other Income/Expense	6.9M	-219K	1.39M	20.86K
Pretax Income+	4.37M	-2.93M	-1.19M	-2.89M
Pretax Margin %	-	-	-	-
Income Tax+	0	0	33.99K	18.84K
Effective Tax Rate %	1%	1%	1.03%	1.01%
Net Income+	4.37M	-2.93M	-1.23M	-2.9M
Net Margin %	-	-	-	-
Net Income Growth %	-	-1.67%	0.58%	-1.37%
Net Income (Continuing)	4.37M	-2.93M	-1.23M	-2.9M
Discontinued Operations	0	0	0	0
Minority Interest	0	0	0	0
EPS (Diluted)+	0.13	0.30	-0.15	-0.40
EPS Growth %	-	1.31%	-1.5%	-1.67%
EPS (Basic)	0.13	0.30	-0.15	-0.40
Diluted Shares Outstanding	34.5M	34.43M	8.01M	7.19M
Basic Shares Outstanding	34.5M	34.43M	8.01M	7.19M
Dividend Payout Ratio	-	-	-	-

Balance Sheet

	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	421.92K	360.65K	210.88K	812.66K
Cash & Short-Term Investments	336.23K	5.05M	434K	804.54K
Cash Only	336.23K	5.05M	434K	804.54K
Short-Term Investments	0	0	0	0
Accounts Receivable	1.26K	100K	945K	6.46K
Days Sales Outstanding	-	-	-	-
Inventory	0	0	0	0
Days Inventory Outstanding	-	-	-	-
Other Current Assets	84.44K	-6.47M	-1.17M	1.66K
Total Non-Current Assets+	276.02M	15.13M	4.29M	2.02M
Property, Plant & Equipment	0	1K	1K	0
Fixed Asset Turnover	-	-	-	-
Goodwill	0	0	0	0
Intangible Assets	0	0	0	0
Long-Term Investments	276.02M	0	0	2.02M
Other Non-Current Assets	0	15.13M	4.29M	0
Total Assets+	276.44M	15.49M	4.5M	2.83M
Asset Turnover	-	-	-	-
Asset Growth %	-	-0.94%	-0.71%	-0.37%
Total Current Liabilities+	1.38M	3.59M	5.16M	8.68M
Accounts Payable	0	508K	933K	0
Days Payables Outstanding	-	-	-	-
Short-Term Debt	90K	16.5M	16.05M	5.12M
Deferred Revenue (Current)	0	0	0	0
Other Current Liabilities	1.29M	-14.06M	-12.88M	3.56M
Current Ratio	0.31x	0.10x	0.04x	0.09x
Quick Ratio	0.31x	0.10x	0.04x	0.09x
Cash Conversion Cycle	-	-	-	-
Total Non-Current Liabilities+	20.19M	10.6M	10.04M	10.02M
Long-Term Debt	0	0	0	0
Capital Lease Obligations	0	0	0	0
Deferred Tax Liabilities	0	0	0	0
Other Non-Current Liabilities	20.19M	10.6M	10.04M	10.02M
Total Liabilities	21.57M	14.19M	15.19M	18.7M
Total Debt+	90K	16.5M	16.05M	5.12M
Net Debt	-246.23K	11.45M	15.62M	4.32M
Debt / Equity	0.00x	12.75x	-	-
Debt / EBITDA	0.02x	-	-	-
Net Debt / EBITDA	-0.06x	-	-	-
Interest Coverage	-	-12.37x	-14.78x	-21.04x
Total Equity+	254.87M	1.29M	-10.69M	-15.87M
Equity Growth %	-	-0.99%	-9.26%	-0.48%
Book Value per Share	7.39	0.04	-1.33	-2.21
Total Shareholders' Equity	254.87M	1.29M	-10.69M	-15.87M
Common Stock	276M	15.13M	4.05M	1.76M
Retained Earnings	-21.13M	-13.97M	-14.88M	-17.52M
Treasury Stock	0	0	0	0
Accumulated OCI	0	0	0	-160.68K
Minority Interest	0	0	0	0

Cash Flow

	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-1.22M	-869K	-3.35M	-3.11M
Operating CF Margin %	-	-	-	-
Operating CF Growth %	-	0.29%	-2.85%	0.07%
Net Income	4.37M	-2.93M	-4.98M	-2.9M
Depreciation & Amortization	0	0	0	0
Stock-Based Compensation	0	0	0	0
Deferred Taxes	0	0	0	0
Other Non-Cash Items	-6.9M	900K	0	-157.62K
Working Capital Changes	1.32M	1.16M	1.64M	-44.54K
Change in Receivables	0	0	0	48K
Change in Inventory	0	0	0	0
Change in Payables	0	89K	425K	0
Cash from Investing+	-276M	0	-819K	1.97M
Capital Expenditures	0	0	0	0
CapEx % of Revenue	-	-	-	-
Acquisitions	-	-	-	-
Investments	-	-	-	-
Other Investing	0	0	-698.48K	0
Cash from Financing+	277.55M	5.92M	-450K	1.05M
Debt Issued (Net)	-	-	-	-
Equity Issued (Net)	-	-	-	-
Dividends Paid	0	0	0	0
Share Repurchases	-	-	-	-
Other Financing	-5.52M	0	10.66M	0
Net Change in Cash	-	-	-	-
Free Cash Flow+	-1.22M	-869K	-3.35M	-3.11M
FCF Margin %	-	-	-	-
FCF Growth %	-	0.29%	-2.85%	0.07%
FCF per Share	-0.04	-0.03	-0.42	-0.43
FCF Conversion (FCF/Net Income)	-0.28x	0.30x	2.73x	1.07x
Interest Paid	0	503K	0	0
Taxes Paid	0	0	0	0

Key Ratios

Metric	2021	2022	2023	2024
Return on Equity (ROE)	1.71%	-2.29%	-	-
Return on Invested Capital (ROIC)	-	-1.52%	-21.95%	-
Debt / Equity	0.00x	12.75x	-	-
Interest Coverage	-	-12.37x	-14.78x	-21.04x
FCF Conversion	-0.28x	0.30x	2.73x	1.07x

Frequently Asked Questions

Growth & Financials

Liminatus Pharma, Inc. Class A Common Stock (LIMN) grew revenue by 0.0% over the past year. Growth has been modest.

Liminatus Pharma, Inc. Class A Common Stock (LIMN) reported a net loss of $2.6M for fiscal year 2024.

Dividend & Returns

Liminatus Pharma, Inc. Class A Common Stock (LIMN) had negative free cash flow of $10.4M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener